



ABX-PF2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Larry Ronald Helms
Group Art Unit : 1642
Applicants : Bruce D. Cohen et al.
Application No. : 10/038,591
Confirmation No. : 1445
Filed : January 4, 2002
For : ANTIBODIES TO INSULIN-LIKE GROWTH
FACTOR I RECEPTOR

New York, New York
October 4, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SECOND
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

In accordance with 37 C.F.R. § 1.97, this Statement is accompanied by a check in the amount of \$180.00, in payment of the fee as set forth in 37 C.F.R. § 1.17(p).

The Director is hereby authorized to charge payment of any additional

fees required in connection with the accompanying Information Disclosure Statement, or

10/08/2004 RFEKADU1 00000086 10030531

01 FC:1806

100.00 GP

credit any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

Jane T. Gunnison

Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants

FISH & NEAVE LLP

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1105

Tel.: (212) 596-9000

Fax: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.S.
Postal Service as First-
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1470
Alexandria, VA. 22313-1470

Clara J. Schuman Goodman
Clara J. Schuman Goodman

[Signature]
Signature of Person Signing



ABX-PF2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Larry Ronald Helms
Group Art Unit : 1642
Applicants : Bruce D. Cohen et al.
Application No. : 10/038,591
Confirmation No. : 1445
Filed : January 4, 2002
For : ANTIBODIES TO INSULIN-LIKE GROWTH
FACTOR I RECEPTOR

New York, New York
October 4, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants hereby make of record the documents listed below. Copies of these documents are enclosed.¹

UNITED STATES PATENTS

United States Patent 4,399,216 issued to Axel et al. on August 16, 1983.

¹ For the Examiner's convenience, applicants have also enclosed a completed Form PTO-1449, listing these documents.

United States Patent 4,510,245, issued to Cousens et al. on April 9, 1985.

United States Patent 4,634,665, issued to Axel et al. on January 6, 1987.

United States Patent 4,740,461, issued to Kaufman on April 26, 1988.

United States Patent 4,912,040, issued to Kaufman et al. on March 27, 1990.

United States Patent 4,959,455, issued to Clark et al. on September 25, 1990.

United States Patent 4,968,615, issued to Koszinowski et al. on November 6, 1990.

United States Patent 5,151,510, issued to Stec et al. on September 29, 1992.

United States Patent 5,168,062, issued to Stinski on December 1, 1992.

United States Patent 5,179,017, issued to Axel et al. on January 12, 1993.

United States Patent 5,223,409, issued to Ladner et al. on June 29, 1993.

United States Patent 5,530,101, issued to Queen et al. June 25, 1996.

United States Patent 5,545,806, issued to Lonberg et al. August 13, 1996.

United States Patent 5,545,807, issued to Surani et al. August 13, 1996.

United States Patent 5,585,089, issued to Queen et al. on December 17, 1996.

United States Patent 5,587,458, issued to King et al. on December 24, 1996.

United States Patent 5,591,669, issued to Krimpenfort et al. January 7, 1997.

United States Patent 5,612,205, issued to Kay et al. on March 18, 1997.

United States Patent 5,625,126, issued to Lonberg et al. April 29, 1997.

United States Patent 5,625,825, issued to Rostoker et al. on April 29, 1997

United States Patent 5,633,425, issued to Lonberg et al. on May 27, 1997.

United States Patent 5,643,763, issued to Dunn et al. on July 1, 1997.

United States Patent 5,661,016, issued to Lonberg et al. on August 26, 1997.

United States Patent 5,693,761, issued to Queen et al. on December 2, 1997.

United States Patent 5,693,792, issued to Torii et al. on December 2, 1997.

United States Patent 5,714,350, issued to Co et al. on February 3, 1998.

United States Patent 5,721,367, issued to Kay et al. February 24, 1998.

United States Patent 5,741,957, issued to Deboer et al. on April 21, 1998.

United States Patent 5,747,498, issued to Schnur et al. on May 5, 1998.

United States Patent 5,750,172, issued to Meade et al. on May 12, 1998.

United States Patent 5,756,687, issued to Denman et al. on May 26, 1998.

United States Patent 5,770,429, issued to Lonberg et al. on June 23, 1998.

United States Patent 5,777,085, issued to Co et al. on July 7, 1998.

United States Patent 5,789,215, issued to Berns et al. on August 4, 1998.

United States Patent 5,789,650, issued to Lonberg et al. on August 4, 1998.

United States Patent 5,792,783, issued to Tang et al. on August 11, 1998.

United States Patent 5,814,318, issued to Lonberg et al. on September 29, 1998.

United States Patent 5,827,690, issued to Meade et al. on October 27, 1998.

United States Patent 5,834,504, issued to Tang et al. on November 10, 1998.

United States Patent 5,861,510, issued to Piscopio et al. on January 19, 1999.

United States Patent 5,863,949, issued to Robinson et al. on January 26, 1999.

United States Patent 5,877,305, issued to Huston et al. on March 2, 1999.

United States Patent 5,883,113, issued to Tang et al. on March 16, 1999.

United States Patent 5,886,020, issued to Tang et al. on March 23, 1999.

United States Patent 5,886,152, issued to Nakatani et al. on March 23, 1999.

United States Patent 5,916,771, issued to Hori et al. on June 29, 1999.

United States Patent 5,939,598, issued to Kucherlapati et al. on August 17, 1999.

United States Patent 5,985,615, issued to Jakobovits et al. on November 16, 1999.

United States Patent 5,994,619, issued to Stice et al. on November 30, 1999.

United States Patent 5,998,209, issued to Jakobovits et al. on December 7, 1999.

United States Patent 6,054,297, issued to Carter et al. on April 25, 2000.

United States Patent 6,075,181, issued to Kucherlapati et al. on June 13, 2000.

United States Patent 6,091,001, issued to Jakobovits et al. on July 18, 2000.

United States Patent 6,114,598, issued to Kucherlapati et al. on September 5, 2000.

United States Patent 6,130,364, issued to Jakobovits et al. on October 10, 2000.

FOREIGN PATENT DOCUMENTS

European Patent 0 216 846, (Kenten et al.) published April 8, 1987.

European Patent 0 256 055, (Wilson et al.) published February 24, 1988.

European Patent 0 323 997, (Bebbington) published July 19, 1989.

European Patent 0 338 841, (Bebbington et al) published October 25, 1989.

European Patent Publication 0 606 046, (MacPherson et al.) published July 13, 1994.

European Patent Publication 0 780 386, (Bender et al.) published June 25, 1997.

European Patent 0 818 442, (Burgess) published January 14, 1998.

European Patent Publication 0 931 788, (Dack et al.) published July 28, 1999.

European Patent 1 004 578, (Laird et al.) published May 31, 2000.

PCT Patent Application WO 90/05719, (Campion et al.) published May 31, 1990.

PCT Patent Application WO 91/10741, (Kucherlapati et al.) published July 25, 1991.

PCT Patent Application WO 91/17271, (Dower et al.) published November 14, 1991.

PCT Patent Application WO 92/01047, (McCafferty et al.) January 23, 1992.

PCT Patent Application WO 92/02190, (Silverman) published February 20, 1992.

PCT Patent Application WO 92/09690, (Garrard et al.) June 11, 1992.

PCT Patent Application WO 92/15679, (Markland et al.) September 17, 1992.

PCT Patent Application WO 92/18619, (Kang et al.) published October 29, 1992.

PCT Patent Application WO 92/20791, (Winter et al.) published November 26, 1992.

PCT Patent Application WO 93/01288, (Breitling et al.) published January 21, 1993.

PCT Patent Application WO 93/06213, (Hoogenboom et al.) published April 1, 1993.

PCT Patent Application WO 94/02602, (Kuncherlapati et al.) published February 3, 1994.

PCT Patent Application WO 95/19970, (Bridges et al.) published July 27, 1995.

PCT Patent Application WO 95/21613, (Gazit et al.) published August 17, 1995.

PCT Patent Application WO 96/27583, (Robinson et al.) published September 12, 1996.

PCT Patent Application WO 96/33172, (Piscopio et al.) published October 24, 1996.

PCT Patent Application WO 96/33735, (Kucherlapati et al.) published October 31, 1996.

PCT Patent Application WO 96/34096, (Kucherlapati et al.) published October 31, 1996.

PCT Patent Application WO 97/13760, (McKeown et al.) published April 17, 1997.

PCT Patent Application WO 97/22596, (Lohmann et al.) published June 26, 1997.

PCT Patent Application WO 97/32856, (Thomas et al.) published September 12, 1997.

PCT Patent Application WO 98/02434, (Cockerill et al.) published January 22, 1998.

PCT Patent Application WO 98/02437, (Cockerill et al.) published January 22, 1998.

PCT Patent Application WO 98/02438, (Cockerill et al.) published January 22, 1998.

PCT Patent Application WO 98/03516, (Reiter) published January 29, 1998.

PCT Patent Application WO 98/07697, (Blumenkopf et al.) published February 26, 1998.

PCT Patent Application WO 98/14451, (Bold et al.) published April 9, 1998.

PCT Patent Application WO 98/16654, (Hori et al.) published April 23, 1998.

PCT Patent Application WO 98/24893, (Jakobovits et al.) published June 11, 1998.

PCT Patent Application WO 98/30566, (Burgess et al.) published July 16, 1998.

PCT Patent Application WO 98/33768, (Robinson et al.) published August 6, 1998.

PCT Patent Application WO 98/34915, (Robinson) published August 13, 1998.

PCT Patent Application WO 98/34918, (McClure) published August 13, 1998.

PCT Patent Application WO 98/50356, (Tang et al.) published November 12, 1998.

PCT Patent Application WO 98/50433, (Jakobovits et al.) published November 12, 1998.

PCT Patent Application WO 98/54093, (Bilodeau et al.) published December 3, 1998.

PCT Patent Application WO 99/07675, (Robinson) published February 18, 1999.

PCT Patent Application WO 99/10349, (Hennequin et al.) published March 4, 1999.

PCT Patent Application WO 99/16755, (Bilodeau et al.) published April 8, 1999.

PCT Patent Application WO 99/24440, (Munchhof et al.) published May 20, 1999.

PCT Patent Application WO 99/29667, (Dack et al.) published June 17, 1999.

PCT Patent Application WO 99/35132, (Cockerill et al.) published July 15, 1999.

PCT Patent Application WO 99/35146, (Carter et al.) published July 15, 1999.

PCT Patent Application WO 99/45031, (Davis et al.) published September 10, 1999.

PCT Patent Application WO 99/52889, (Reiter) published October 21, 1999.

PCT Patent Application WO 99/52910, (Robinson) published October 21, 1999.

PCT Patent Application WO 99/53049, (Davis et al.) published October 21, 1999.

PCT Patent Application WO 99/61422, (Tang et al.) published December 2, 1999.

PCT Patent Application WO 99/62890, (Larson et al.) published December 9, 1999.

PCT Patent Application WO 00/09560, (Gallo et al.) published February 24, 2000.

PCT Patent Application WO 00/37504, (Hanson et al.) published June 29, 2000.

OTHER DOCUMENTS

Altschul et al., "Basic local alignment search tool," *Journal of Molecular Biology*, 215(1):403-410 (1990).

Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," *Nucleic Acids Research*, 25(17):3389-402 (1997).

Arteaga et al., "Interference of the IGF system as a strategy to inhibit breast cancer growth," *Breast Cancer Research Treatment*, 22:101-106 (1992).

Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," *Journal of Clinical Investigation*, 84:1418-1423 (1989).

Barbas et al., "Assembly of combinatorial antibody libraries on phage surfaces: the gene III site," *PNAS*, 88:7978-7982 (1991).

Barkan, "New options for diagnosing and treating acromegaly," *Cleveland Clinic Journal of Medicine*, 65(7):343-349 (1998).

Bayes-Genis et al., "The insulin-like growth factor axis. A review of atherosclerosis and restenosis," *Circulation Research*, 86(2):125-130 (2000).

Bird et al., "Single-chain antigen-binding proteins," *Science*, 242:423-426 (1988).

Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," *Science*, 253:164-170 (1991).

Butler et al., "Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression," *Cancer Research*, 58:3021-3027 (1998).

Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins," *Journal of Molecular Biology*, 196:901-917 (1987).

Chothia et al., "Conformations of immunoglobulin hypervariable regions," *Nature*, 342:877-883 (1989).

Clackson et al., "Making antibody fragments using phage display libraries," *Nature*, 352:624-628 (1991).

- Cullen et al., "Insulin-like growth factor receptor expression and function in human breast cancer," *Cancer Research*, 50: 48-53 (1990).
- Cullen et al., "Glutathione S-transferase π amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors," *Cancer Research*, 63: 8097-8102 (2003).
- D'Ambrosio et al., "A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells *in vivo* and inhibits tumorigenesis," *Cancer Research*, 56:4013-4020 (1996).
- DiGiovanni et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," *PNAS*, 97(7):3455-3460 (2000).
- Drexhage et al., "Endocrine autoimmune diseases," *Netherlands Journal of Medicine*, 45:285-293 (1994).
- Du Pasquier, "Evolution of the immune system," *Fundamental Immunology, Second Edition*, edited by William E. Paul, Raven Press Ltd., NY, 139-165 (1989).
- Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," *Journal of Medicinal Chemistry*, 30:1229-1239 (1987).
- Fagerstam et al., "Detection of antigen-antibody interactions by surface plasmon resonance. Applications to epitope mapping," *Journal of Molecular Recognition*, 3:(5,6):208-214 (1990).
- Fanger et al., "Production and use of anti-FcR bispecific antibodies," *Immunomethods*, 4:72-81 (1994).
- Fauchere, "Elements for the rational drug design of peptides drugs," *Advances in Drug Research*, 15:29-69 (1986).
- Foekens et al., "Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer," *Cancer Research*, 49:7002-7009 (1989).
- Freed et al., "Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture," *Journal of Molecular Endocrinology*, 3:183-189 (1989).
- Fuchs et al., "Targeting recombinant antibodies to the surface of *Escherichia coli*: fusion to a peptidoglycan associated lipoprotein," *Biotechnology*, 9:1369-1372 (1991).
- Galfre et al., "Preparation of monoclonal antibodies: strategies and procedures," *Methods in Enzymology*, 73:3-46 (1981).

- Garrad et al., "F_{AB} assembly and enrichment in a monovalent phage display system," *Biotechnology*, 9:1373-1377 (1991).
- Geran, et al., "Protocols for screening chemical agents and natural products against animal tumors and other biological systems," *Cancer Chemotherapy Reports*, 3(2):1-104 (1972).
- Goldring et al., "Cytokines and cell growth control," *Critical Reviews in Eukaryotic Gene Expression*, 1:31-326 (1991).
- Gonnet et al., "Exhaustive matching of the entire protein sequence database," *Science*, 256:1443-1445 (1992).
- Gram et al., "In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library," *PNAS*, 89:3576-3580 (1992).
- Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," *Nature Genetics*, 7:13-21 (1994).
- Green et al., "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," *Journal of Experimental Medicine*, 188(3):483-495 (1998).
- Griffiths et al., "Human anti-self antibodies with high specificity from phage display libraries," *The EMBO Journal*, 12(2):725-734 (1993).
- Grimberg et al., "Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis," *Journal of Cellular Physiology*, 183:1-9 (2000).
- Guo et al., "Characterization of insulinlike growth factor I receptors in human colon cancer," *Gastroenterology*, 102(4):1101-1108 (1992).
- Harrington et al., "c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines," *The EMBO Journal*, 13(14):3286-3295 (1994).
- Hawkins et al., "Selection of phage antibodies by binding affinity mimicking affinity maturation," *Journal of Molecular Biology*, 226:889-896 (1992).
- Hay et al., "Bacteriophage cloning and *Escherichia coli* expression of a human IgM Fab," *Hum. Antibod. Hybridomas*, 3:81-85 (1992).
- Hockenbery et al., "Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death," *Nature*, 348:334-336 (1990).

Holliger et al., "Diabodies: small bivalent and bispecific antibody fragments," *PNAS*, 90:6444-6448 (1993).

Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," *Nucleic Acids Research*, 19(15):4133-4137 (1991).

Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," *Science*, 246:1275-1281 (1989).

Huston et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*," *PNAS*, 85:5879-5883 (1988).

Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," *Protein Engineering*, 10(8): 949-957 (1997).

Jiang et al., "Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor," *Oncogene*, 18:6071-6077 (1999).

Johnsson et al., "Comparison of methods for immobilization to carboxymethyl dextran sensor surfaces by analysis of the specific activity of monoclonal antibodies," *Journal of Molecular Recognition*, 8:125-131 (1995).

Johnsson et al., "Immobilization of proteins to a carboxymethyl-dextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors," *Analytical Biochemistry*, 198:268-277 (1991).

Jonsson et al., "Introducing a biosensor based technology for real-time biospecific interaction analysis," *Ann. Biologie Clinique.*, 51:19-26 (1993).

Jonsson et al., "Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology," *BioTechniques*, 11(5):620-627 (1991).

Kaiser et al., "Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer," *Journal of Cancer Research and Clinical Oncology*, 119(11):665-668 (1993).

Kalebic et al., "In vivo treatment with antibody against IGF-I receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34^{cdc2}," *Cancer Research*, 54:5531-5534 (1994)

Kim et al., "Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling," *Journal of Biological Chemistry*, 273:34543-34550 (1998).

Lane, "A death in the life of p53," *Nature*, 362:786-787 (1993).

LaPlanche et al., "Phosphorothiolate-modified oligodeoxyribonucleotides, III. NMR and UV spectroscopic studies of the R_p-R_p, S_p-S_p, and R_p-S_p duplexes, [d(GG₅AATTCC)]₂, derived from diastereomeric O-ethyl phosphorothioates," *Nucleic Acids Research*, 14(22):9081-9093 (1986).

Laron, "Clinical use of somatomedin-1," *Pediatric Drugs*, 1(3):155-159 (1999).

LeRoith et al., "Molecular and cellular aspects of the insulin-like growth factor I receptor," *Endocrine Reviews*, 16(2):143-163 (1995).

Li et al., "Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain," *Journal of Biological Chemistry*, 269:32558-32564 (1994).

Macaulay, "Insulin-like growth factors and cancer," *British Journal of Cancer*, 65:311-320 (1992).

Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," *Cancer Research*, 50:2511-2517 (1990).

Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," *The EMBO Journal*, 13(22): 5303-5309 (1994).

McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," *Nature*, 348:552-554 (1990).

McDonnell et al., "bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation," *Cell*, 57:79-88 (1989).

Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," *Nature Genetics*, 15:146-156 (1997).

Moody et al., "Growth factor and peptide receptors in small cell lung cancer," *Life Sciences*, 52:1161-1173 (1993).

Moyer et al., "Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase," *Cancer Research*, 57:4838-4848 (1997).

Nakanishi et al., "Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro," *Journal of Clinical Investigation*, 82:354-359 (1988).

Pearson, "Empirical statistical estimates for sequence similarity searches," *Journal of Molecular Biology*, 276:71-84 (1998).

Pearson, "Rapid and sensitive sequence comparison with FASTP and FASTA," *Methods in Enzymology*, 183:63-98 (1990).

Pearson, "Flexible sequence similarity searching with the FASTA3 program package," *Methods in Molecular Biology*, 132:185-219 (2000).

Pearson, "Using the FASTA program to search protein and DNA sequence databases," *Methods in Molecular Biology*, 24:307-331 (1994).

Pearson, "Effective protein sequence comparison," *Methods in Enzymology*, 266:227-258 (1996).

Pietrzkowski et al., "Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors," *Cell Growth & Differentiation*, 3:199-205 (1992).

Pietrzkowski et al., "Roles of insullike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells," *Molecular and Cellular Biology*, 12(9):3883-3889 (1992).

Poljak, "Production and structure of diabodies," *Structure*, 2:1121-1123 (1994).

Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice," *Journal of Pharmacology and Experimental Therapeutics*, 291(2):739-748 (1999).

Pollak et al., "Presence of somatomedin receptors on primary human breast and colon carcinomas," *Cancer Letters*, 38:223-230 (1987).

Prager et al., "Dominant negative inhibition of tumorigensis *in vivo* by human insulin-like growth factor I receptor mutant," *PNAS*, 91:2181-2185 (1994).

Remacle-Bonnet et al., "Expression of Type I, but not Type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line," *Journal of Clinical Endocrinology and Metabolism*, 75(2):609-616 (1992).

Resnicoff et al., "The insulin-like growth factor I receptor protects tumor cells from Apoptosis *in vivo*," *Cancer Research*, 55:2463-2469 (1995).

- Resnicoff et al., "Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors," *Cancer Research*, 55:3739-3741 (1995).
- Rizo et al., "Constrained peptides: models of bioactive peptides and protein substructures," *Annual Review of Biochemistry*, 61:387-418 (1992).
- Rodriguez-Tarduchy et al., "Insulin-like growth factor-I inhibits apoptosis in Il-3-dependent hemopoietic cells," *Journal of Immunology*, 149(2):535-540 (1992).
- Rosen et al., "Circulating IGF-I: new perspectives for a new century," *Trends in EndocrinologyMetabolism*, 10(4):136-141 (1999).
- Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," *Cancer Research*, 53:2475-2478 (1993).
- Sell et al., "Insulin-like growth factor 1 (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis," *Cancer Research*, 55:303-306 (1995).
- Smith et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor," *Nature Medicine*, 5(12): 1390-1395 (1999).
- Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," *Journal of the American Chemical Society*, 106(20):6077-6079 (1984).
- Stein et al., "Physiochemical properties of phosphorothioate oligodeoxynucleotides," *Nucleic Acids Research*, 16(8):3209-3221 (1988).
- Tappy et al., "Antibodies to insulin-like growth factor 1 receptors in diabetes and other disorders," *Diabetes*, 37:1708-1714 (1988).
- Thompson et al., "Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature," *Pediatric Research*, 32(4):455-459 (1988).
- Thornton et al., "Prediction of progress at last," *Nature*, 354(14):105-106 (1991).
- Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," *The EMBO Journal*, 10(12):3655-3659 (1991).
- Traunecker et al., "Janusin: new molecular design for bispecific reagents," *International Journal of Cancer*, 7:51-52 (1992).


- Trojan et al., "Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA," *Science*, 259:94-97 (1993).
- Uhlmann et al., "Antisense oligonucleotides: a new therapeutic principle," *Chemical Reviews*, 90(4):543-584 (1990).
- Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity," *Cell*, 61:203-212 (1990).
- Ullrich et al., "Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity," *The EMBO Journal*, 5(10):2503-2512 (1986).
- Veber et al., "The design of metabolically-stable peptide analogs," *TINS*, 8(9):392-396 (1985).
- Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*," *Nature*, 341:544-546 (1989).
- Weightman et al., "Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy," *Autoimmunity*, 16:251-257 (1993).
- Williams, "Programmed cell death: apoptosis and oncogenesis," *Cell*, 65:1097-1098 (1991).
- Winter et al., "Humanized antibodies," *Immunology Today*, 14(6):243-246 (1993).
- Wraight et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides," *Nature Biotechnology*, 18:521-526 (2000).
- Wright et al., "Genetically engineered antibodies: progress and prospects," *Critical Reviews in Immunology*, 12:(3,4)125-168 (1992).
- Yee et al., "Analysis of insulin-like growth factor 1 gene expression in malignancy: evidence for a paracrine role in human breast cancer," *Molecular Endocrinology*, 3(3):509-517 (1989).
- Yee et al., "Insulin-like growth factor II mRNA expression in human breast cancer," *Cancer Research*, 48:6691-6696 (1988).
- Zon et al., "Phosphorothioate oligonucleotides," *Oligonucleotides and Analogues: A Practical Approach*, 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991).
- Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," *Anti-Cancer Drug Design*, 6:539-568 (1991).

REMARKS

Applicants request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application and (2) printed on any patent issuing from this application. Applicants also request that the Examiner initial the enclosed Form PTO-1449 in the appropriate places to indicate that the documents have been considered and return a copy of the initialed Form to the undersigned in accordance with MPEP § 609 and § 2001.06(b).

Applicants are submitting this statement after mailing of an Office Action on the merits but before the mailing of a final Office Action or a Notice of Allowance. Accordingly, applicants have enclosed the required fee [37 C.F.R. §§ 1.98 and 1.17(p)].

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants

FISH & NEAVE LLP

Customer No. 1473


1251 Avenue of the Americas

New York, New York 10020-1105

Tel.: (212) 596-9000

Fax: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service in First
Class Mail in an envelope
Addressed to:
Comptroller for Patents
P.O. Box 100
Alexandria, VA 22313-1000 on


Claire J. Yamin-van Goochman
Signature

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,399,216	08/16/83	Axel et al.	435	6	
	4,510,245	04/09/85	Cousens et al.	435	172.3	
	4,634,665	01/06/87	Axel et al.	435	68	
	4,740,461	04/26/88	Kaufman	435	68	
	4,912,040	03/27/90	Kaufman et al.	435	69.6	
	4,959,455	09/25/90	Clark et al.	530	351	
	4,968,516	11/06/90	Koszinowski et al.	435	172.3	
	5,151,510	09/29/92	Stec et al.	536	27	
	5,168,062	12/01/92	Stinski	435	240.2	
	5,179,017	01/12/93	Axel et al.	435	240.2	
	5,223,409	06/29/93	Ladner et al.	435	69.7	
	5,530,101	06/25/96	Queen et al.	530	387.3	
	5,545,806	08/13/96	Lonberg et al.	800	2	
	5,545,807	08/13/96	Surani et al.	800	2	
	5,585,089	12/17/96	Queen et al.	424	133.1	
	5,587,458	12/24/96	King et al.	530	387.3	
	5,591,669	01/07/97	Krimpenfort et al.	800	2	
	5,612,205	03/18/97	Kay et al.	435	172.3	
	5,625,126	04/29/97	Lonberg et al.	800	2	
	5,625,825	04/29/97	Rostoker et al.	395	730	
	5,633,425	05/27/97	Lonberg et al.	800	2	
	5,643,763	07/01/97	Dunn et al.	435	91.1	
	5,661,016	08/26/97	Lonberg et al.	435	172.3	
	5,693,761	12/02/97	Queen et al.	536	23.53	
	5,693,792	12/02/97	Torii et al.	540	358	
	5,714,350	02/03/98	Co et al.	435	69.6	
	5,721,367	02/24/98	Kay et al.	800	2	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642


UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,741,957	04/21/98	Deboer et al.	800	2	
	5,747,498	05/05/98	Schnur et al.	514	259	
	5,750,172	05/12/98	Meade et al.	426	580	
	5,756,687	05/26/98	Denman et al.	530	412	
	5,770,429	06/23/98	Lonberg et al.	435	240.2	
	5,777,085	07/07/98	Co et al.	530	388.23	
	5,789,215	08/04/98	Berns et al.	435	172.3	
	5,789,650	08/04/98	Lonberg et al.	800	2	
	5,792,783	08/11/98	Tang et al.	514	397	
	5,814,318	09/29/98	Lonberg et al.	424	184.1	
	5,827,690	10/27/98	Meade et al.	435	69.6	
	5,834,504	11/10/98	Tang et al.	514	418	
	5,861,510	01/19/99	Piscopio et al.	544	131	
	5,863,949	01/26/99	Robinson et al.	514	575	
	5,877,305	03/02/99	Huston et al.	536	23.53	
	5,883,113	03/16/99	Tang et al.	514	418	
	5,886,020	03/23/99	Tang et al.	514	418	
	5,886,152	03/23/99	Nakatani et al.	530	387.3	
	5,916,771	06/29/99	Hori et al.	435	69.6	
	5,939,598	08/17/99	Kucherlapati et al.	800	25	
	5,985,615	11/16/99	Jakobovits et al.	435	69.6	
	5,994,619	11/30/99	Stice et al.	800	21	
	5,998,209	12/07/99	Jokobovits et al.	435	463	
	6,054,297	04/25/00	Carter et al.	435	69.6	
	6,075,181	06/13/00	Kucherlapati et al.	800	25	
	6,091,001	07/18/00	Jakobovits et al.	800	18	
	6,114,598	09/05/00	Kucherlapati et al.	800	18	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,130,364	10/10/00	Jakobovits et al.	800	6	

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 216 846	04/08/87	EPO	C12N	15/00		
	0 256 055	02/24/88	EPO	C12N	15/52		
	0 323 997	07/19/89	EPO	C12N	15/12		
	0 338 841	10/25/89	EPO	C12N	15/00		
	0 606 046	07/13/94	EPO	C07D	213/42		
	0 780 386	06/25/97	EPO	C07D	309/08		
	0 818 442	01/14/98	EPO	C07C	317/44		
	0 931 788	07/28/99	EPO	C07C	311/03		
	1 004 578	05/31/00	EPO	C07D	207/28		
	WO 90/05719	05/31/90	PCT	C07C	323/62		
	WO 91/10741	07/25/91	PCT	C12P	21/06		
	WO 91/17271	11/14/91	PCT	C12Q	1/70		
	WO 92/01047	01/23/92	PCT	C12N	15/00		
	WO 92/02190	02/20/92	PCT	A61C	7/00		
	WO 92/09690	06/11/92	PCT	C12N	15/00		
	WO 92/15679	09/17/92	PCT	C12N	15/10		
	WO 92/18619	10/29/92	PCT	C12N	7/01		
	WO 92/20791	11/26/92	PCT	C12N	15/00		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 93/01288	01/21/93	PCT	C12N	15/13		
	WO 93/06213	04/01/93	PCT	C12N	15/00		
	WO 94/02602	02/03/94	PCT	C12N	15/00		
	WO 95/19970	07/27/95	PCT	C07D	239/70		
	WO 95/21613	08/17/95	PCT	A16K	31/24		
	WO 96/27583	09/12/96	PCT	C07C	311/29		
	WO 96/33172	10/24/96	PCT	C07D	211/96		
	WO 96/33735	10/31/96	PCT	A61K	39/00		
	WO 96/34096	10/31/96	PCT	C12N	15/00		
	WO 97/13760	04/17/97	PCT	C07D	239/70		
	WO 97/22596	06/26/97	PCT	C07D	239/94		
	WO 97/32856	09/12/97	PCT	C07D	239/94		
	WO 98/02434	01/22/98	PCT	C07D	405/04		
	WO 98/02437	01/22/98	PCT	C07D	471/04		
	WO 98/02438	01/22/98	PCT	C07D	471/04		
	WO 98/03516	01/29/98	PCT	C07F	9/30		
	WO 98/07697	02/26/98	PCT	C07D	211/58		
	WO 98/14451	04/09/98	PCT	C07D	487/04		
	WO 98/16654	04/23/98	PCT	C12P	21/00		
	WO 98/24893	06/11/98	PCT	C12N	15/00		
	WO 98/30566	07/16/98	PCT	C07D	493/08		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/33768	08/06/98	PCT	C07C	311/29		
	WO 98/34915	08/13/98	PCT	C07C	317/44		
	WO 98/34918	08/13/98	PCT	C07D	211/62		
	WO 98/50356	11/12/98	PCT	C07D	207/09		
	WO 98/50433	11/12/98	PCT	C07K	16/00		
	WO 98/54093	12/03/98	PCT	C01D	293/72		
	WO 99/07675	02/18/99	PCT	C07C	311/29		
	WO 99/10349	03/04/99	PCT	C07D	487/04		
	WO 99/16755	04/08/99	PCT	C07D	235/08		
	WO 99/24440	05/20/99	PCT	C07D	495/04		
	WO 99/29667	06/17/99	PCT	C07D	211/16		
	WO 99/35132	07/15/99	PCT	C07D	239/94		
	WO 99/35146	07/15/99	PCT	C07D	471/04		
	WO 99/45031	09/10/99	PCT	C07K	16/28		
	WO 99/52889	10/21/99	PCT	C07D	309/14		
	WO 99/52910	10/21/99	PCT	C07D	493/08		
	WO 99/53049	10/21/99	PCT	C12N	15/10		
	WO 99/61422	12/02/99	PCT	C07D	209/04		
	WO 99/62890	12/09/99	PCT	C07D	275/03		
	WO 00/09560	02/24/00	PCT	C07K	16/00		
	WO 00/37504	06/29/00	PCT	C07K	16/28		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Altschul et al., "Basic local alignment search tool," <i>Journal of Molecular Biology</i> , 215(1):403-410 (1990)
	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucleic Acids Research</i> , 25(17):3389-402 (1997)
	Arteaga et al., "Interference of the IGF system as a strategy to inhibit breast cancer growth," <i>Breast Cancer Research Treatment</i> , 22:101-106 (1992)
	Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," <i>Journal of Clinical Investigation</i> , 84:1418-1423 (1989)
	Barbas et al., "Assembly of combinatorial antibody libraries on phage surfaces: the gene III site," <i>PNAS</i> , 88:7978-7982 (1991)
	Barkan, "New options for diagnosing and treating acromegaly," <i>Cleveland Clinic Journal of Medicine</i> , 65(7):343-349 (1998)
	Bayes-Genis et al., "The insulin-like growth factor axis. A review of atherosclerosis and restenosis," <i>Circulation Research</i> , 86(2):125-130 (2000)
	Bird et al., "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-426 (1988)
	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991)
	Butler et al., "Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression," <i>Cancer Research</i> , 58:3021-3027 (1998)
	Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins," <i>Journal of Molecular Biology</i> , 196:901-917 (1987)
	Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989)
	Clackson et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642


- | | |
|--|--|
| | Cullen et al., "Insulin-like growth factor receptor expression and function in human breast cancer," <i>Cancer Research</i> , 50: 48-53 (1990) |
| | Cullen et al., "Glutathione S-transferase π amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors," <i>Cancer Research</i> , 63: 8097-8102 (2003) |
| | D'Ambrosio et al., "A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells <i>in vivo</i> and inhibits tumorigenesis," <i>Cancer Research</i> , 56:4013-4020 (1996) |
| | DiGiovanni et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," <i>PNAS</i> , 97(7):3455-3460 (2000) |
| | Drexhage et al., "Endocrine autoimmune diseases," <i>Netherlands Journal of Medicine</i> , 45:285-293 (1994) |
| | Du Pasquier, "Evolution of the immune system," <i>Fundamental Immunology, Second Edition</i> , edited by William E. Paul, Raven Press Ltd., NY, 139-165 (1989) |
| | Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," <i>Journal of Medicinal Chemistry</i> , 30:1229-1239 (1987) |
| | Fagerstam et al., "Detection of antigen-antibody interactions by surface plasmon resonance. Applications to epitope mapping," <i>Journal of Molecular Recognition</i> , 3:(5,6):208-214 (1990) |
| | Fanger et al., "Production and use of anti-FcR bispecific antibodies," <i>Immunomethods</i> , 4:72-81 (1994) |
| | Fauchere, "Elements for the rational drug design of peptides drugs," <i>Advances in Drug Research</i> , 15:29-69 (1986) |
| | Foekens et al., "Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer," <i>Cancer Research</i> , 49:7002-7009 (1989) |
| | Freed et al., "Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture," <i>Journal of Molecular Endocrinology</i> , 3:183-189 (1989) |
| | Fuchs et al., "Targeting recombinant antibodies to the surface of <i>Escherichia coli</i> : fusion to a peptidoglycan associated lipoprotein," <i>Biotechnology</i> , 9:1369-1372 (1991) |
| | Galfre et al., "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

	Garrad et al., "F _{AB} assembly and enrichment in a monovalent phage display system," <i>Biotechnology</i> , 9:1373-1377 (1991)
	Geran, et al., "Protocols for screening chemical agents and natural products against animal tumors and other biological systems," <i>Cancer Chemotherapy Reports</i> , 3(2):1-104 (1972)
	Goldring et al., "Cytokines and cell growth control," <i>Critical Reviews in Eukaryotic Gene Expression</i> , 1:31-326 (1991)
	Gonnet et al., "Exhaustive matching of the entire protein sequence database," <i>Science</i> , 256:1443-1445 (1992)
	Gram et al., " <i>In vitro</i> selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library," <i>PNAS</i> , 89:3576-3580 (1992)
	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human lg heavy and light chain YACs," <i>Nature Genetics</i> , 7:13-21 (1994)
	Green et al., "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," <i>Journal of Experimental Medicine</i> , 188(3):483-495 (1998)
	Griffiths et al., "Human anti-self antibodies with high specificity from phage display libraries," <i>The EMBO Journal</i> , 12(2):725-734 (1993)
	Grimberg et al., "Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis," <i>Journal of Cellular Physiology</i> , 183:1-9 (2000)
	Guo et al., "Characterization of insulinlike growth factor I receptors in human colon cancer," <i>Gastroenterology</i> , 102(4):1101-1108 (1992)
	Harrington et al., "c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines," <i>The EMBO Journal</i> , 13(14):3286-3295 (1994)
	Hawkins et al., "Selection of phage antibodies by binding affinity mimicking affinity maturation," <i>Journal of Molecular Biology</i> , 226:889-896 (1992)
	Hay et al., "Bacteriophage cloning and <i>Escherichia coli</i> expression of a human IgM Fab," <i>Hum. Antibod. Hybridomas</i> , 3:81-85 (1992)
	Hockenbery et al., "Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death," <i>Nature</i> , 348:334-336 (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY. DOCKET NO.
ABX-PF2

APPLICANT
Bruce D. Cohen et al.

FILING DATE
January 4, 2002

APPLN. NO.
10/038,591

CONFIRMATION
NO. 1445


GROUP
1642

	Holliger et al., "Diabodies: small bivalent and bispecific antibody fragments," <i>PNAS</i> , 90:6444-6448 (1993)
	Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Research</i> , 19(15):4133-4137 (1991)
	Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," <i>Science</i> , 246:1275-1281 (1989)
	Huston et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>PNAS</i> , 85:5879-5883 (1988)
	Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," <i>Protein Engineering</i> , 10(8): 949-957 (1997)
	Jiang et al., "Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor," <i>Oncogene</i> , 18:6071-6077 (1999)
	Johnsson et al., "Comparison of methods for immobilization to carboxymethyl dextran sensor surfaces by analysis of the specific activity of monoclonal antibodies," <i>Journal of Molecular Recognition</i> , 8:125-131 (1995)
	Johnsson et al., "Immobilization of proteins to a carboxymethyl-dextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors," <i>Analytical Biochemistry</i> , 198:268-277 (1991)
	Jonsson et al., "Introducing a biosensor based technology for real-time biospecific interaction analysis," <i>Ann. Biologie Clinique.</i> , 51:19-26 (1993)
	Jonsson et al., "Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology," <i>BioTechniques</i> , 11(5):620-627 (1991)
	Kaiser et al., "Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer," <i>Journal of Cancer Research and Clinical Oncology</i> , 119(11):665-668 (1993)
	Kalebic et al., "In vivo treatment with antibody against IGF-I receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34 ^{cdc2} ," <i>Cancer Research</i> , 54:5531-5534 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591APPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

	Kim et al., "Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling," <i>Journal of Biological Chemistry</i> , 273:34543-34550 (1998)
	Lane, "A death in the life of p53," <i>Nature</i> , 362:786-787 (1993)
	LaPlanche et al., "Phosphorothiolate-modified oligodeoxyribonucleotides, III. NMR and UV spectroscopic studies of the R _p -R _p , S _p -S _p , and R _p -S _p duplexes, [d(GG ₅ AATTCC)] ₂ , derived from diastereomeric O-ethyl phosphorothioates," <i>Nucleic Acids Research</i> , 14(22):9081-9093 (1986)
	Laron, "Clinical use of somatomedin-1," <i>Pediatric Drugs</i> , 1(3):155-159 (1999)
	LeRoith et al., "Molecular and cellular aspects of the insulin-like growth factor I receptor," <i>Endocrine Reviews</i> , 16(2):143-163 (1995)
	Li et al., "Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain," <i>Journal of Biological Chemistry</i> , 269:32558-32564 (1994)
	Macaulay, "Insulin-like growth factors and cancer," <i>British Journal of Cancer</i> , 65:311-320 (1992)
	Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <i>Cancer Research</i> , 50:2511-2517 (1990)
	Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," <i>The EMBO Journal</i> , 13(22): 5303-5309 (1994)
	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> , 348:552-554 (1990)
	McDonnell et al., "bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation," <i>Cell</i> , 57:79-88 (1989)
	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genetics</i> , 15:146-156 (1997)
	Moody et al., "Growth factor and peptide receptors in small cell lung cancer," <i>Life Sciences</i> , 52:1161-1173 (1993)
	Moyer et al., "Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase," <i>Cancer Research</i> , 57:4838-4848 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
ABX-PF2APPLICANT
Bruce D. Cohen et al.FILING DATE
January 4, 2002APPLN. NO.
10/038,591CONFIRMATION
NO. 1445GROUP
1642

	Nakanishi et al., "Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro," <i>Journal of Clinical Investigation</i> , 82:354-359 (1988)
	Pearson, "Empirical statistical estimates for sequence similarity searches," <i>Journal of Molecular Biology</i> , 276:71-84 (1998)
	Pearson, "Rapid and sensitive sequence comparison with FASTP and FASTA," <i>Methods in Enzymology</i> , 183:63-98 (1990)
	Pearson, "Flexible sequence similarity searching with the FASTA3 program package," <i>Methods in Molecular Biology</i> , 132:185-219 (2000)
	Pearson, "Using the FASTA program to search protein and DNA sequence databases," <i>Methods in Molecular Biology</i> , 24:307-331 (1994)
	Pearson, "Effective protein sequence comparison," <i>Methods in Enzymology</i> , 266:227-258 (1996)
	Pietrzkowski et al., "Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors," <i>Cell Growth & Differentiation</i> , 3:199-205 (1992)
	Pietrzkowski et al., "Roles of insulinlike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells," <i>Molecular and Cellular Biology</i> , 12(9):3883-3889 (1992)
	Poljak, "Production and structure of diabodies," <i>Structure</i> , 2:1121-1123 (1994)
	Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 291(2):739-748 (1999)
	Pollak et al., "Presence of somatomedin receptors on primary human breast and colon carcinomas," <i>Cancer Letters</i> , 38:223-230 (1987)
	Prager et al., "Dominant negative inhibition of tumorigenesis <i>in vivo</i> by human insulin-like growth factor I receptor mutant," <i>PNAS</i> , 91:2181-2185 (1994)
	Remacle-Bonnet et al., "Expression of Type I, but not Type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line," <i>Journal of Clinical Endocrinology and Metabolism</i> , 75(2):609-616 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642


	Resnicoff et al., "The insulin-like growth factor I receptor protects tumor cells from Apoptosis <i>in vivo</i> ," <i>Cancer Research</i> , 55:2463-2469 (1995)
	Resnicoff et al., "Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors," <i>Cancer Research</i> , 55:3739-3741 (1995)
	Rizo et al., "Constrained peptides: models of bioactive peptides and protein substructures," <i>Annual Review of Biochemistry</i> , 61:387-418 (1992)
	Rodriguez-Tarduchy et al., "Insulin-like growth factor-I inhibits apoptosis in Il-3-dependent hemopoietic cells," <i>Journal of Immunology</i> , 149(2):535-540 (1992)
	Rosen et al., "Circulating IGF-I: new perspectives for a new century," <i>Trends in Endocrinology Metabolism</i> , 10(4):136-141 (1999)
	Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," <i>Cancer Research</i> , 53:2475-2478 (1993)
	Sell et al., "Insulin-like growth factor 1 (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis," <i>Cancer Research</i> , 55:303-306 (1995)
	Smith et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor," <i>Nature Medicine</i> , 5(12): 1390-1395 (1999)
	Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," <i>Journal of the American Chemical Society</i> , 106(20):6077-6079 (1984)
	Stein et al., "Physiochemical properties of phosphorothioate oligodeoxynucleotides," <i>Nucleic Acids Research</i> , 16(8):3209-3221 (1988)
	Tappy et al., "Antibodies to insulin-like growth factor 1 receptors in diabetes and other disorders," <i>Diabetes</i> , 37:1708-1714 (1988)
	Thompson et al., "Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature," <i>Pediatric Research</i> , 32(4):455-459 (1988)
	Thornton et al., "Prediction of progress at last," <i>Nature</i> , 354(14):105-106 (1991)
	Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>The EMBO Journal</i> , 10(12):3655-3659 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

	Traunecker et al., "Janusin: new molecular design for bispecific reagents," <i>International Journal of Cancer</i> , 7:51-52 (1992)
	Trojan et al., "Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA," <i>Science</i> , 259:94-97 (1993)
	Uhlmann et al., "Antisense oligonucleotides: a new therapeutic principle," <i>Chemical Reviews</i> , 90(4):543-584 (1990)
	Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity," <i>Cell</i> , 61:203-212 (1990)
	Ullrich et al., "Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity," <i>The EMBO Journal</i> , 5(10):2503-2512 (1986)
	Veber et al., "The design of metabolically-stable peptide analogs," <i>TINS</i> , 8(9):392-396 (1985)
	Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (1989)
	Weightman et al., "Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy," <i>Autoimmunity</i> , 16:251-257 (1993)
	Williams, "Programmed cell death: apoptosis and oncogenesis," <i>Cell</i> , 65:1097-1098 (1991)
	Winter et al., "Humanized antibodies," <i>Immunology Today</i> , 14(6):243-246 (1993)
	Wraight et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides," <i>Nature Biotechnology</i> , 18:521-526 (2000)
	Wright et al., "Genetically engineered antibodies: progress and prospects," <i>Critical Reviews in Immunology</i> , 12:(3,4)125-168 (1992)
	Yee et al., "Analysis of insulin-like growth factor 1 gene expression in malignancy: evidence for a paracrine role in human breast cancer," <i>Molecular Endocrinology</i> , 3(3):509-517 (1989)
	Yee et al., "Insulin-like growth factor II mRNA expression in human breast cancer," <i>Cancer Research</i> , 48:6691-6696 (1988)
	Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," *Anti-Cancer Drug Design*, 6:539-568 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.